Janssen Pharmaceuticals obtained the FDA's approval to market Topamax, or topiramate, for the prevention of migraine in adolescents 12 to 17. Topamax is the first FDA-approved drug for this indication in this age group. The drug was previously approved for treatment of seizure and migraine prevention in adults.
Janssen's migraine drug wins expanded FDA approval
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||